

# Spero R Cataland

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1905714/spero-r-cataland-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

115  
papers

2,994  
citations

30  
h-index

53  
g-index

119  
ext. papers

3,877  
ext. citations

5.7  
avg. IF

5.35  
L-index

#	Paper	IF	Citations
115	Clinical relapse of immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination.. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2022</b> , 6, e12658	5.1	1
114	Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study. <i>Blood</i> , <b>2021</b> , 138, 2080-2080	2.2	
113	Preferences for Accessing Patient Reported Outcomes and Health Information Among Thrombotic Thrombocytopenic Purpura Survivors. <i>Blood</i> , <b>2021</b> , 138, 3039-3039	2.2	
112	Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies. <i>Blood</i> , <b>2021</b> , 138, 769-769	2.2	
111	Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. <i>Kidney International Reports</i> , <b>2021</b> , 6, 1603-1613	4.1	7
110	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. <i>Blood Advances</i> , <b>2021</b> , 5, 2137-2141	7.8	6
109	Redefining outcomes in immune TTP: an international working group consensus report. <i>Blood</i> , <b>2021</b> , 137, 1855-1861	2.2	28
108	Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	23
107	Cardiovascular Disease is a Leading Cause of Mortality among TTP Survivors in Clinical Remission. <i>Blood Advances</i> , <b>2021</b> ,	7.8	5
106	In vitro diagnostics for the medical dermatologist. Part II: Hypercoagulability tests. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 301-310	4.5	0
105	Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 1587-1594	7.1	1
104	Atypical haemolytic uraemic syndrome: a case report of a rare cause of reversible cardiomyopathy. <i>European Heart Journal - Case Reports</i> , <b>2020</b> , 4, 1-6	0.9	4
103	The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. <i>Kidney International</i> , <b>2020</b> , 97, 1287-1296	9.9	43
102	Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry. <i>Kidney International Reports</i> , <b>2020</b> , 5, 1161-1171	4.1	4
101	Relapse Prediction Model for Immune-Mediated Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , <b>2020</b> , 136, 8-9	2.2	
100	Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune-mediated thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , <b>2020</b> , 189, e18-e20	4.5	3
99	Cardiovascular Disease Is a Leading Cause of Death in Thrombotic Thrombocytopenic Purpura (TTP) Survivors. <i>Blood</i> , <b>2020</b> , 136, 22-23	2.2	4

98	Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 479-484	15.4	28
97	Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E76-E77	7.1	13
96	ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2496-2502	15.4	57
95	SO054ONE-YEAR EFFICACY AND SAFETY OF THE LONG ACTING C5 INHIBITOR RAVULIZUMAB FOR THE TREATMENT OF ATYPICAL HAEMOLYTIC URAEMIC SYNDROME (AHUS) IN ADULTS. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> , 35,	4.3	2
94	ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2486-2495	15.4	36
93	Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2503-2512	15.4	9
92	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. <i>Blood</i> , <b>2020</b> , 136, 2103-2117	2.2	23
91	Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. <i>Kidney International Reports</i> , <b>2019</b> , 4, 1568-1576	4.1	21
90	Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. <i>Intensive Care Medicine</i> , <b>2019</b> , 45, 1518-1539	14.5	19
89	Eculizumab deposits in vessel walls in thrombotic microangiopathy. <i>Kidney International</i> , <b>2019</b> , 96, 761-768	9.8	10
88	Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 92-94	59.2	38
87	Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab. <i>Blood</i> , <b>2019</b> , 134, 1099-1099	2.2	5
86	Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies. <i>Blood</i> , <b>2019</b> , 134, 4908-4908	2.2	1
85	Severely Deficient ADAMTS13 Activity Predicts Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Pregnancy. <i>Blood</i> , <b>2019</b> , 134, 1098-1098	2.2	1
84	Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations. <i>Blood</i> , <b>2019</b> , 134, 90-90	2.2	1
83	Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study. <i>Blood</i> , <b>2019</b> , 134, 931-931	2.2	1
82	A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , <b>2019</b> , 134, 2377-2377	2.2	
81	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen. <i>Blood</i> , <b>2019</b> , 134, 2365-2365	2.2	0

80	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity. <i>Blood</i> , <b>2019</b> , 134, 2366-2366	2.2	
79	Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study. <i>Blood</i> , <b>2019</b> , 134, 1093-1093	2.2	
78	African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , <b>2019</b> , 134, 1066-1066	2.2	
77	Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 913-916	4.4	1
76	Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 335-346	59.2	337
75	Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia. <i>Journal of Oncology Pharmacy Practice</i> , <b>2019</b> , 25, 567-576	1.7	5
74	Novel therapies in thrombotic thrombocytopenic purpura. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2018</b> , 2, 19-26	5.1	17
73	The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis. <i>Blood</i> , <b>2018</b> , 132, 903-910	2.2	34
72	Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , <b>2018</b> , 132, 373-373	2.2	2
71	Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , <b>2018</b> , 132, 3739-3739	2.2	3
70	Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study. <i>Blood</i> , <b>2018</b> , 132, 3744-3744	2.2	2
69	Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study. <i>Blood</i> , <b>2018</b> , 132, 1142-1142 <sup>2</sup>	2.2	3
68	Prospective Analysis of Complement Activation in Allogeneic Transplant Recipients and Correlation with Transplant Associated Thrombotic Microangiopathy (TA-TMA) and Acute Graft Versus Host Disease (aGVHD). <i>Blood</i> , <b>2018</b> , 132, 4572-4572	2.2	
67	No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: The experience from the Ohio State University Registry. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E73-E75	7.1	7
66	FP250FACIT-FATIGUE SCORES IN ADULT PATIENTS AT ENROLLMENT INTO THE GLOBAL AHUS REGISTRY. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i114-i114	4.3	1
65	Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. <i>Blood Advances</i> , <b>2018</b> , 2, 2619-2628	7.8	30
64	Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura. <i>Thrombosis Research</i> , <b>2017</b> , 151, 51-56	8.2	19
63	None of the above: thrombotic microangiopathy beyond TTP and HUS. <i>Blood</i> , <b>2017</b> , 129, 2857-2863	2.2	55

62	Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. <i>Blood Advances</i> , <b>2017</b> , 1, 2075-2082	7.8	39
61	Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , <b>2017</b> , 130, LBA-1 <sup>2</sup> -LBA-1 <sup>6</sup>		
60	Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 511-22	59.2	322
59	Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. <i>Clinical Colorectal Cancer</i> , <b>2016</b> ,	3.8	12
58	A Prospective, Randomized Study of Cyclosporine or Corticosteroids As an Adjunct to Plasma Exchange for the Treatment of Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , <b>2016</b> , 128, 133-133	2.2	3
57	Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. <i>American Journal of Kidney Diseases</i> , <b>2016</b> , 68, 84-93	7.4	162
56	Headache prevalence following recovery from TTP and aHUS. <i>Annals of Hematology</i> , <b>2015</b> , 94, 1473-6	3	7
55	Effect of blood sampling, processing, and storage on the measurement of complement activation biomarkers. <i>American Journal of Clinical Pathology</i> , <b>2015</b> , 143, 558-65	1.9	50
54	Acute Systolic Heart Failure Associated with Complement-Mediated Hemolytic Uremic Syndrome. <i>Case Reports in Hematology</i> , <b>2015</b> , 2015, 327980	0.7	4
53	Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. <i>Transfusion</i> , <b>2015</b> , 55, 18-24	2.9	29
52	Myocardial Ischemia in Patients with Sickle Cell Disease: A Retrospective Review. <i>Blood</i> , <b>2015</b> , 126, 2189-2189	2.1	1
51	Eculizumab therapy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 438-9	4.7	1
50	Diagnosis and management of complement mediated thrombotic microangiopathies. <i>Blood Reviews</i> , <b>2014</b> , 28, 67-74	11.1	36
49	Clinical utility of complement biomarkers in the diagnosis and treatment of acute thrombotic microangiopathies. <i>British Journal of Haematology</i> , <b>2014</b> , 167, 697-8	4.5	
48	How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. <i>Blood</i> , <b>2014</b> , 123, 2478-84	2.2	96
47	Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. <i>Blood</i> , <b>2014</b> , 123, 3733-8	2.2	112
46	Profound neurological injury in a patient with atypical hemolytic uremic syndrome. <i>Annals of Hematology</i> , <b>2013</b> , 92, 557-8	3	17
45	Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , <b>2013</b> , 11, 1925-7	15.4	36

44	Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation. <i>Annals of Hematology</i> , <b>2013</b> , 92, 845-6	3	32
43	Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies. <i>European Journal of Internal Medicine</i> , <b>2013</b> , 24, 486-91 <sup>9</sup>	3.1	35
42	Myeloid growth factors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2013</b> , 11, 1266-90 <sup>3</sup>	9.3	49
41	Venous thromboembolic disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2013</b> , 11, 1402-29	7.3	73
40	Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Adult Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS). <i>Blood</i> , <b>2013</b> , 122, 2179-2179	2.2	2
39	Diagnostic and Prognostic Values Of ADAMTS13 Activity Measured During Daily Plasma Exchange Therapy In Patients With Acquired TTP. <i>Blood</i> , <b>2013</b> , 122, 1079-1079	2.2	
38	Alternative and Terminal Complement Pathway Biomarkers At Presentation More Precisely Define The Clinical Diagnosis Of aHUS. <i>Blood</i> , <b>2013</b> , 122, 3552-3552	2.2	
37	The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. <i>British Journal of Haematology</i> , <b>2012</b> , 157, 501-3	4.5	36
36	Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , <b>2012</b> , 87, 430-2	7.1	59
35	Recent advances in the management of atypical hemolytic uremic syndrome. <i>Clinical Advances in Hematology and Oncology</i> , <b>2012</b> , 10, 537-9	0.6	
34	Practical issues in ADAMTS13 testing and emerging therapies in thrombotic thrombocytopenic purpura. <i>Seminars in Hematology</i> , <b>2011</b> , 48, 242-50	4	6
33	ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome. <i>Haematologica</i> , <b>2011</b> , 96, 1521-7 <sup>6</sup>	6.6	23
32	3 Rs: rituximab, remission, relapse. <i>Blood</i> , <b>2011</b> , 118, 1711-2	2.2	1
31	ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy. <i>British Journal of Haematology</i> , <b>2011</b> , 153, 277-9	4.5	15
30	Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , <b>2011</b> , 86, 87-9	7.1	41
29	Long-term, sub-clinical cardiac and renal complications in patients with multiple relapses of thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , <b>2010</b> , 149, 623-5	4.5	11
28	Validation of claims-based diagnostic codes for idiopathic thrombotic thrombocytopenic purpura in a commercially-insured population. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 103, 1203-9	7	7
27	Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. <i>Haematologica</i> , <b>2010</b> , 95, 1555-62	6.6	95

26	Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 65, 319-24	3.5	4
25	TTP disease course is independent of myeloma treatment and response. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 304-6	7.1	15
24	Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 976-7	7.1	28
23	Comparison of Clinical Outcomes Between Initial and Relapsed Events of Thrombotic Thrombocytopenic Purpura In a Large TTP Cohort.. <i>Blood</i> , <b>2010</b> , 116, 1439-1439	2.2	
22	Longitudinal Analysis of VWF Multimerization Patterns In a well-defined TTP Cohort. <i>Blood</i> , <b>2010</b> , 116, 4308-4308	2.2	
21	Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura. <i>European Journal of Haematology</i> , <b>2009</b> , 83, 559-64	3.8	23
20	Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. <i>British Journal of Haematology</i> , <b>2008</b> , 141, 651-8	4.5	94
19	A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 2444-9	12.9	71
18	Common clinical variables predict warfarin maintenance dose and therapeutic resistance. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2008</b> , 25, 101-101	5.1	
17	Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , <b>2008</b> , 83, 911-5	7.1	34
16	Lower ADAMTS13 Activity and Higher Bethesda Units of Antibody Inhibitor in Early Remission Are Associated with a Higher Probability of TTP Exacerbation.. <i>Blood</i> , <b>2008</b> , 112, 2299-2299	2.2	
15	An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , <b>2007</b> , 136, 146-9	4.5	64
14	Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. <i>British Journal of Haematology</i> , <b>2007</b> , 139, 486-93	4.5	49
13	Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 437-44	4	4
12	Low ADAMTS13 Activity in Clinical Remission Predicts the Risk of TTP Relapses.. <i>Blood</i> , <b>2007</b> , 110, 4018-4018		
11	Myocardial ischemia and right ventricular dysfunction in adult patients with sickle cell disease. <i>Haematologica</i> , <b>2006</b> , 91, 1329-35	6.6	36
10	Immunotherapy for thrombotic thrombocytopenic purpura. <i>Current Opinion in Hematology</i> , <b>2005</b> , 12, 359-63	3.3	18
9	Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).. <i>Blood</i> , <b>2005</b> , 106, 145-145	2.2	9

8	Cyclosporine Alone for the Treatment of Early Recurrences of TTP.. <i>Blood</i> , <b>2005</b> , 106, 1236-1236	2.2	
7	A Rapid Test for the Diagnosis of Thrombotic Thrombocytopenic Purpura Using SELDI-TOF-Mass Spectrometry.. <i>Blood</i> , <b>2005</b> , 106, 2660-2660	2.2	
6	Evaluation of Qualitative Platelet Disorders in Patients with Hemophilia.. <i>Blood</i> , <b>2005</b> , 106, 3987-3987	2.2	
5	Myocardial Ischemia without Coronary Artery Obstruction in Patients with Sickle Cell Disease.. <i>Blood</i> , <b>2005</b> , 106, 3180-3180	2.2	
4	Cyclosporine and Plasma Exchange Is Superior to Corticosteroids and Plasma Exchange as Initial Therapy of TTP.. <i>Blood</i> , <b>2005</b> , 106, 1235-1235	2.2	
3	Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. <i>Blood</i> , <b>2003</b> , 101, 425-32	2.2	196
2	Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , <b>2001</b> , 41, 297-307	1.9	12
1	Antibody therapy of acute and chronic leukemias. <i>Current Pharmaceutical Biotechnology</i> , <b>2001</b> , 2, 357-672.6		4